Blood test for immune markers in skin cancer patients on cemiplimab
Treatments studied
Part of Cancer, Immune system & allergy, Skin clinical trials.
This trial is testing whether a new blood test can predict how well the drug cemiplimab works for skin cancer and if it causes side effects. It may help doctors better match treatments to patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your blood counts and liver/kidney function are within certain safe ranges (your doctor can check)
- You do not have a serious active infection like HIV, hepatitis B, or hepatitis C
- You have not had a strong immune-suppressing treatment for an autoimmune disease recently
- You do not have untreated or growing brain metastases
- You are willing to use effective contraception if you or your partner could become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug (cemiplimab) injected directly into early-stage skin cancer (squamous cell carcinoma) to see if it can shrink or cure the cancer before surgery. It may help patients avoid more extensive surgery or reduce the chance of the cancer coming back.
This study looks at whether a blood test called D-dimer can predict how well cemiplimab (an immunotherapy drug) works for advanced skin cancer. If you are already planning to get cemiplimab, the study will collect your D-dimer results and follow your progress to see if the test helps guide treatment.
This trial tests a drug called cemiplimab (Libtayo) for kidney transplant recipients who have advanced skin cancer (cutaneous squamous cell carcinoma). The treatment aims to help your immune system fight the cancer while managing your transplant medicines to keep your kidney healthy.
This early-phase study tests cemiplimab (an immune therapy that helps your immune system attack cancer) given before surgery. It aims to shrink tumors and improve outcomes for people with Merkel cell cancer or certain locally advanced skin squamous cell cancers (CSCC).
This trial tests cemiplimab, an immunotherapy drug, as a first treatment for advanced basal cell carcinoma that cannot be removed with surgery or radiation. The goal is to see if it can shrink or control the cancer.
This study tests different ways of using the drug cemiplimab to treat advanced basal cell skin cancer that cannot be removed with surgery or treated with radiation. It aims to find the most effective approach to shrink or control the cancer.
Hear when a new Cutaneous Squamous Cell Carcinoma (CSCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.